Print
Email
Print Edition Stories
Cambridge RNAi-focused therapeutics firm Alnylam Pharmaceuticals Inc. has formed a collaboration deal with Vancouver-based Precision NanoSystems Inc. The collaboration centers around small lipid nanoparticle (sLNPs) development using microfluidics.
A news release from both companies today pointed out the potential growth in biodistribution applications for sNLPs.
No financial terms of the deal were disclosed.
The collaboration marks the latest in a series of research deals Alnylam has made with Canadian companies. Earlier this month, Alnylam extended a research collaboration with AlCana Technologies Inc. and The University of Britich Columbia and focused on RNAi therapeutics delivery from catatonic lipids used in lipid nanoparticles.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
